Markets:

Overview

News

Currencies

International

Treasuries

Amgen (NQ:AMGN)

407.83 +17.81 (+4.57%)

Streaming Delayed Price Updated: 4:00 PM EDT, Aug 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

69 70 Next >

Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet ↗

September 26, 2025

Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de

Via Benzinga

Topics Government World Trade

European Advisory Panel Recommends Two AstraZeneca Drugs For Approval ↗

September 22, 2025

AstraZeneca and Amgen secure CHMP support for Tezspire in nasal polyps and Koselugo in neurofibromatosis after strong Phase 3 trial results.

Via Benzinga

Big Pharma's Epicenter Shift: Eli Lilly and the Reshaping of the Weight-Loss Drug Market

September 22, 2025

The pharmaceutical industry is currently witnessing a transformative battle for dominance in the burgeoning weight-loss drug market, with Eli Lilly (NYSE: LLY) firmly at the forefront. What was once a...

Via MarketMinute

Topics Economy Intellectual Property

How Is The Market Feeling About Amgen? ↗

September 17, 2025

Via Benzinga

Zai Lab To Await More Trial Data Before Filing For Regulatory Approval For Experimental Cancer Drug ↗

September 03, 2025

Via Stocktwits

Johnson & Johnson's Uninterrupted Dividend Growth: Innovation in Medicine and MedTech Drives Strong Q2 2025 Performance

September 22, 2025

Johnson & Johnson (NYSE: JNJ), the global healthcare titan, has once again underscored its formidable market position and unwavering commitment to shareholder value, reporting a robust second quarter...

Via MarketMinute

Topics Artificial Intelligence Intellectual Property

Eli Lilly's Ascent: A New Era in Obesity Treatment Driven by Zepbound and Orforglipron

September 22, 2025

Eli Lilly and Company (NYSE: LLY) has reported a stellar second quarter for 2025, significantly exceeding market expectations and cementing its position as a dominant force in the burgeoning obesity...

Via MarketMinute

Topics Economy

The Pharmaceutical Revolution: AI, Gene Therapies, and Obesity Drugs Reshape a Trillion-Dollar Market

September 19, 2025

The global pharmaceutical sector stands at the precipice of a monumental transformation, driven by an unprecedented convergence of scientific breakthroughs, technological innovation, and evolving...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Why Amgen (AMGN) Stock Is Trading Up Today

September 19, 2025

Shares of biotech company Amgen (NASDAQ:AMGN) jumped 3.4% in the afternoon session after a European regulatory body recommended approving its drug, Uplizna, for treating a rare autoimmune disorder.

Via StockStory

Topics Artificial Intelligence

Friday's session: top gainers and losers in the S&P500 index ↗

September 19, 2025

Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday.

Via Chartmill

Eli Lilly Poised for Blockbuster Q3 2025 with Skyrocketing EPS and Revenue Projections

September 19, 2025

Pharmaceutical giant Eli Lilly and Company (NYSE:LLY) is gearing up for a stellar third quarter of 2025, with analysts projecting massive earnings per share (EPS) and revenue growth. The optimistic...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

GLP-1 Titans Clash: Eli Lilly Challenges Novo Nordisk's Dominance in a Spiraling Market Battle

September 19, 2025

The pharmaceutical industry is witnessing an unprecedented showdown as Eli Lilly (NYSE: LLY) rapidly encroaches upon Novo Nordisk's (NYSE: NVO) long-held lead in the burgeoning GLP-1 (glucagon-like...

Via MarketMinute

Lilly's Oncology Momentum Soars: Olomorasib Gains Breakthrough Status, Jaypirca Achieves Landmark Clinical Successes

September 19, 2025

Eli Lilly and Company (NYSE: LLY) is making significant waves in the oncology landscape with a series of major announcements concerning two of its innovative cancer therapies: Olomorasib and Jaypirca...

Via MarketMinute

EMA Backs Amgen Drug For Rare Autoimmune Disorder ↗

September 19, 2025

European Medicines Agency's panel recommends expanding Amgen's Uplizna to treat IgG4-related disease, with trial data showing reduced flares and higher remission rates.

Via Benzinga

Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session. ↗

September 19, 2025

Let's take a look at the S&P500 stocks that are experiencing unusual volume in today's session.

Via Chartmill

Uncover the latest developments among S&P500 stocks in today's session. ↗

September 19, 2025

Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday.

Via Chartmill

The Weight of Progress: A New Era Dawns for Anti-Obesity Drugs, Reshaping Markets and Health

September 15, 2025

The global anti-obesity drug market is experiencing an unprecedented surge, driven by groundbreaking advancements in pharmacotherapy, particularly the advent of highly effective GLP-1 receptor...

Via MarketMinute

2 Healthcare Dividend Stocks to Buy and Hold ↗

September 14, 2025

These drugmakers have competitive yields and have increased their dividends at a good clip.

Via The Motley Fool

Topics Intellectual Property

The Dawn of a New Era: How GLP-1s, AI, and Robotic Surgery Are Reshaping Healthcare and Investment

September 12, 2025

The healthcare industry is currently experiencing a transformative "golden age," a period marked by an unprecedented surge in scientific breakthroughs and technological advancements. This era is...

Via MarketMinute

Topics Artificial Intelligence Bankruptcy Economy

1 Cash-Producing Stock to Target This Week and 2 Facing Challenges

September 11, 2025

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Via StockStory

Amgen Rocatinlimab's Data Shows Potential As Long-Term Therapy For Atopic Dermatitis ↗

September 09, 2025

Amgen and Kyowa Kirin report positive interim results for rocatinlimab, showing long-term safety and sustained efficacy in moderate to severe atopic dermatitis patients.

Via Benzinga

Amgen and Kyowa Kirin Announce Top-Line Results From Rocatinlimab Phase 3 ASCEND Long-Term Extension Study in Adults With Moderate to Severe Atopic Dermatitis

September 09, 2025

From Kyowa Kirin

Via GlobeNewswire

If You'd Invested $10,000 in Amgen Stock (AMGN) 3 Years Ago, Here's How Much You'd Have Today ↗

September 08, 2025

You could have done worse -- or much better.

Via The Motley Fool

Topics Economy

Nvidia Just Went Quantum—And ETFs Are Scrambling To Catch Up ↗

September 04, 2025

Nvidia's $600M investment in Quantinuum highlights quantum computing's commercial evolution and may prompt new ETF strategies in the coming years.

Via Benzinga

Topics ETFs

Why Is Sanofi Stock Falling Thursday? ↗

September 04, 2025

William Blair notes OX40 antibodies rocatinlimab and amlitelimab trail Dupixent in efficacy, with dosing and side effects shaping their market potential.

Via Benzinga

Amgen Faces Setback As Final Data Weakens Case For Gastric Cancer Drug ↗

September 04, 2025

Amgen and Zai Lab's Phase 3 trial of bemarituzumab in gastric cancer showed a weaker survival benefit, shifting focus to the upcoming FORTITUDE-102 results.

Via Benzinga

2 Safe-and-Steady Stocks to Keep an Eye On and 1 Facing Challenges

September 03, 2025

Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies.

Via StockStory

2 Profitable Stocks Worth Your Attention and 1 We Avoid

September 01, 2025

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my...

Via StockStory

2 Dividend Stocks to Hold for the Next 10 Years ↗

August 28, 2025

These stocks offer more than just dividends.

Via The Motley Fool

Topics Economy

2 Large-Cap Stocks to Target This Week and 1 That Underwhelm

August 28, 2025

Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it more challenging to maintain high growth...

Via StockStory

< Previous 1 2

...

9 10 11 12 13 14 15 16 17

...

69 70 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.